Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors

Oncology (Switzerland)

Volumn 83, Issue 3, 2012, Pages 117-127

  Naraev, Boris G ^a   Strosberg, Jonathan R ^b   Halfdanarson, Thorvardur R ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Insulin like growth factor 1 receptor; Mammalian target of rapamycin; Neuroendocrine tumor; Somatostatin; Vascular endothelial growth factor

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CIXUTUMUMAB; EPIDERMAL GROWTH FACTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEFITINIB; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; OXALIPLATIN; PASIREOTIDE; PAZOPANIB; PEGINTERFERON ALPHA2B; ROMIDEPSIN; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; VORINOSTAT;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOID; CARDIOTOXICITY; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; KIDNEY CARCINOMA; LIVER CARCINOMA; METASTASIS; METASTATIC SMALL BOWEL NEUROENDOCRINE TUMOR; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RARE DISEASE; SMALL BOWEL NEUROENDOCRINE TUMOR; SOLID TUMOR; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL DIFFERENTIATION; HISTONE DEACETYLASES; HUMANS; IMMUNOLOGIC FACTORS; INDOLES; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRIDINES; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, SOMATOSTATIN; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863759143     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000339539     Document Type: Article

References (55)

1. Maggard MA, O'Connell JB, Ko CY: Updated population-based review of carcinoid tumors. Ann Surg 2004;240:117-122. (Pubitemid 38808243)
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
3. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
4. Oberg K, Kvols L, Caplin M, Delle FG, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-973. (Pubitemid 39004355)
5. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-275.
6. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
7. Yao JC, Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
8. Meric-Bernstam F, Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278-2287.
9. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St. Peter J, Cherfi A, Oberg KE: Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011;96:3741-3749.
10. Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E, Faivre S: Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Target Oncol 2011;6:119-124.
11. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, viel-Ronen S, Tsao MS, Hedley D, Siu LL: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-1154. (Pubitemid 44660065)
12. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318.
13. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
14. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC, RADIANT-2 Study Group: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.
15. Kulke M, Blaszkowsky LS, Zhu AX, Florio S, Regan E, Ryan DP, Chan JA: Phase I/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). Presented at the 2010 ASCO Gastrointestinal Cancers Symposium, Orlando, January 2010.
16. Jensen RT, Delle Fave G: Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011;364:564-565.
17. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
18. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003;34:18-27. (Pubitemid 36160017)
19. Kazazi-Hyseni F, Beijnen JH, Schellens JH: Bevacizumab. Oncologist 2010;15:819-825.
20. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA: Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-1323.
21. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia W, Lawrence C, Fuchs CS: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(suppl 18).
22. Kunz PL, Kuo T, Zanh JM, Kaiser HL, Norton JA, Visser BC, Longacre TA, Ford JM, Balise RR, Fisher GA: A phase II study of capecitibine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol 2009;16.
23. Venook AP, Ko AH, Tempero MA, Uy J, Weber T, Korn M, Bergsland EK: Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 2011;26.
24. Yao JC, Phan AT, Fogelman D, Ng CS, Jacobs CB, Dagohoy CD, Leary C, Hess KR: Randomized run-in study of bevacizumab (B) and everolimus (E) in low-to intermediategrade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 2010;28(suppl 15).
25. Oudard S, Beuselinck B, Decoene J, Albers P: Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev 2011;37:178-184.
26. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410.
27. Strosberg J, Cheema S, Campos T, Kvols L: Phase II study of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Presented at the 8th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Lisbon, March 2011.
28. ® [prescribing information]: New York: Pfizer Inc. 2011.
29. Phan AT, Yao JC, Fogelman DR, Hess KR, Ng CS, Bullock SA, Malinoski P, Regan E, Kulke M: A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (Sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010;28(suppl 15).
30. Hasskarl J: Sorafenib: recent results. Cancer Res 2010;184:61-70.
31. Hobday TJ, Rubin J, Holen K, Picus J, Donehower RC, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C: MCO44h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2007;25.
32. Castellano D, Capdevila J, Salazar R, Sastre J, Alonzo V, Llanos M, Garcia-Carbonero R, Abad A, Sevilla I, Duran I: Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of Spanish Neuroendocrine Tumor Group (GETNE0801). Presented at the 8th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Lisbon, March 2011.
33. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP: Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;139:742-753.
34. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P: Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-776. (Pubitemid 30091095)
35. Schmid HA, Schoeffter P: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004;80(suppl 1):47-50. (Pubitemid 39382369)
36. Kvols L, Wiedenmann B, Oberg K, Glusman J, O'Dorisio T, de Herder W, Gao B, Arnold R, Anthony L: Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. Presented at the 2006 Gastrointestinal Cancers Symposium, San Francisco, January 2006.
37. Kwekkeboom DJ, de Herder WW, Krenning EP: Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:173-185.
38. Mitsudomi T, Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010;277:301-308.
39. Hobday TJ, Holen K, Donehower RC, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman C: A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2006;24:189S.
40. Chaves J, Saif MW: IGF system in cancer: from bench to clinic. Anticancer Drugs 2011;22:206-212.
41. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T: Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000;60:4573-4581. (Pubitemid 32103642)
42. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ: AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009;8:1095-1105.
43. Rothenberg ML, Tolcher AW, Sarantopoulos J, Rodon J, Friberg G, Deng H, McCafferey I, Hwang Y, Puzanov I: AMG 479 monotherapy to treat patients with advanced GI carcinoid tumors: a subset analysis from the firstinhuman study. Presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, January 2009.
44. Anthony LB, Loehrer PJ, Leong S, Shah MH, Safran H, Senzer NN, Zojwalla NJ, Youssoufian H: Phase II study of cixutumuimab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma. J Clin Oncol 2010;28(suppl 15).
45. Federico M, Bagella L: Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol 2011;1-12.
46. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, Grever M: Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12:3997-4003. (Pubitemid 44078086)
47. Doss HH, Jones SF, Infante JR, Spigel DR, Willcutt N, Lamar R, Barton J, Keegan M, Burris HA: A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J Clin Oncol 2008;26(suppl 15).
48. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9:6316-6325. (Pubitemid 38031815)
49. Larsson DE, Wickstrom M, Hassan S, Oberg K, Granberg D: The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro. Anticancer Res 2010;30:149-156.
50. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M: Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004;10:6111-6118. (Pubitemid 39287516)
51. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085. (Pubitemid 24139577)
52. Xu Y, Ellison C, Martin E, et al: A phase II study of thalidomide in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002;21.
53. Varker KA, Campbell J, Shah MH: Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008;61:661-668.
54. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406. (Pubitemid 46630459)
55. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA: Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-240. (Pubitemid 46121874)